Diabetes research and clinical practice · 2026
Insulin delivery modality and Ramadan fasting interruption, glycemic control, and fear of hypoglycemia in type 1 diabetes: a prospective, multicenter study from Saudi Arabia.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Sofiani Mohammed E, Alharthi Sahar K, Alsuhaibani Mohammad, Alhashem Aliaa, Almurashi Abdulhalim, Almigbal Turky H, Alamoudi Reem M, Zarif Hawazen, Alzaman Naweed, Almehthel Mohammed, Mohammed Sajid, Kalyani Rita R, Klonoff David C
Аннотация
INTRODUCTION: Most people with type 1 diabetes (PWT1D) typically avoid fasting during Ramadan because of dysglycemia risks. We compared efficacy, safety profiles, and fear of hypoglycemia (FOH) during Ramadan fasting in users of four insulin delivery modalities.
METHODS: We compared four treatment groups: automated insulin delivery (AID) (n = 114), sensor augmented pump with predictive-low-glucose suspend (SAP-PLGS) (n = 4), sensor-unintegrated pump (SUP) (n = 24), and multiple daily injections (MDI) + continuous glucose monitoring (CGM) (n = 136).
RESULTS: Pre/during-Ramadan mean percent time in range for the AID, SAP-PLGS, SUP, and MDI-CGM groups was 73.2/73.4, 62/65.5, 57.8/54.6, and 52.1/47.4. The pre/during-Ramadan Glycemia Risk Index for the AID, SAP-PLGS, SUP, and MDI-CGM groups was 30/29, 43/35, 52/55, and 60/64. The proportion of PWT1D achieving a "double target of fasting" (broken fasting ≤ 2 days of Ramadan because of diabetes and TIR > 70%) for the AID, SAP-PLGS, SUP, and MDI-CGM groups was 46.5%, 25%, 12.5%, and 7.35%. AID system users, versus MDI + CGM users, were 22 times likelier to achieve the double target after adjusting for age, sex, employment/insurance status, educational level, and diabetes duration. While the overall FOH score did not significantly differ across the four groups (p > 0.05), AID users had the lowest score and MDI had the highest score (1.23 and 1.63, respectively, p < 0.01) on the survey's behavior subscale.
CONCLUSION: Use of AID during Ramadan fasting was associated with fasting the most days of Ramadan, best glycemic control, and the least frequent hypoglycemia avoidance behaviors. The International Diabetes Federation/Diabetes and Ramadan International Alliance risk calculator should consider a lower risk score for AID technology when used by PWT1D.
METHODS: We compared four treatment groups: automated insulin delivery (AID) (n = 114), sensor augmented pump with predictive-low-glucose suspend (SAP-PLGS) (n = 4), sensor-unintegrated pump (SUP) (n = 24), and multiple daily injections (MDI) + continuous glucose monitoring (CGM) (n = 136).
RESULTS: Pre/during-Ramadan mean percent time in range for the AID, SAP-PLGS, SUP, and MDI-CGM groups was 73.2/73.4, 62/65.5, 57.8/54.6, and 52.1/47.4. The pre/during-Ramadan Glycemia Risk Index for the AID, SAP-PLGS, SUP, and MDI-CGM groups was 30/29, 43/35, 52/55, and 60/64. The proportion of PWT1D achieving a "double target of fasting" (broken fasting ≤ 2 days of Ramadan because of diabetes and TIR > 70%) for the AID, SAP-PLGS, SUP, and MDI-CGM groups was 46.5%, 25%, 12.5%, and 7.35%. AID system users, versus MDI + CGM users, were 22 times likelier to achieve the double target after adjusting for age, sex, employment/insurance status, educational level, and diabetes duration. While the overall FOH score did not significantly differ across the four groups (p > 0.05), AID users had the lowest score and MDI had the highest score (1.23 and 1.63, respectively, p < 0.01) on the survey's behavior subscale.
CONCLUSION: Use of AID during Ramadan fasting was associated with fasting the most days of Ramadan, best glycemic control, and the least frequent hypoglycemia avoidance behaviors. The International Diabetes Federation/Diabetes and Ramadan International Alliance risk calculator should consider a lower risk score for AID technology when used by PWT1D.